Biodexa Pharmaceuticals Plc (BDRX) Earnings History
Annual and quarterly earnings data from 2012 to 2025
Loading earnings history...
BDRX EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
BDRX Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | -967.5% | -2103.4% | -1858.0% |
| 2022 | -631.2% | -1277.8% | -1095.3% |
| 2021 | -705.2% | -1210.7% | -944.6% |
Download Data
Export BDRX earnings history in CSV or JSON format
Free sign-in required to download data
Biodexa Pharmaceuticals Plc (BDRX) Earnings Overview
As of May 8, 2026, Biodexa Pharmaceuticals Plc (BDRX) reported trailing twelve-month net income of -$12M, reflecting +100.0% year-over-year growth. The company earned $-53.57 per diluted share over the past four quarters.
Looking at the long-term picture, BDRX's historical earnings data spans multiple years. The company achieved its highest annual net income of -$4M in fiscal 2012.
Biodexa Pharmaceuticals Plc is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including SIGA (-$4.04T net income, 24.6% margin), NUVB (-$146M net income, -325.3% margin), IMVT (-$464M net income), BDRX has comparable earnings metrics. Compare BDRX vs SIGA →
BDRX Earnings vs Peers
Earnings metrics vs comparable public companies
BDRX Historical Earnings Data (2012–2025)
14 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$6M | -9.0% | -$8M | $-60.00 | - | - |
| 2024 | -$6M | +19.1% | -$9M | $-999999.00 | - | - |
| 2023 | -$7M | +7.5% | -$8M | $-229000.00 | -1858.0% | -2103.4% |
| 2022 | -$8M | -40.2% | -$9M | $-999999.00 | -1095.3% | -1277.8% |
| 2021 | -$5M | +75.4% | -$7M | $-999999.00 | -944.6% | -1210.7% |
| 2020 | -$22M | -120.0% | -$23M | $-999999.00 | -6469.1% | -6717.2% |
| 2019 | -$10M | +2.7% | -$11M | $-999999.00 | -1496.3% | -1679.2% |
| 2018 | -$10M | +11.4% | -$12M | $-999999.00 | -535.0% | -609.6% |
| 2017 | -$12M | -90.0% | -$12M | $-999999.00 | -1183.5% | -1190.7% |
| 2016 | -$6M | +39.0% | -$10M | $-999999.00 | -465.7% | -729.6% |
See BDRX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs BDRX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare BDRX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonBDRX — Frequently Asked Questions
Quick answers to the most common questions about buying BDRX stock.
Is BDRX growing earnings?
BDRX EPS is $-53.57, with earnings growth accelerating to +100.0%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-12M.
What are BDRX's profit margins?
Biodexa Pharmaceuticals Plc net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.
How consistent are BDRX's earnings?
BDRX earnings data spans 2012-2025. The accelerating earnings trend is +100.0% YoY. Historical data enables comparison across business cycles.